We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications.
Location: United States, California, Thousand Oaks
Employees: 51-200
Total raised: $140M
Founded date: 2019
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.05.2021 | Series A | $140M | - |
Mentions in press and media 10
| Date | Title | Description |
| 10.05.2024 | Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration | Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion Broad GCase elevation achieved in NHPs, while signif... |
| 23.07.2021 | Capsida Has a New Facility To Manufacture Treatments for ALS and Friedreich’s Ataxia | It may just be symbolic, but the two-year-old gene therapy Capsida Biotherapeutics built its manufacturing site in the shadow of pharma giant Amgen's headquarters, a wink to its greater ambitions. Capsida's new 15,000-square-foot manufactur... |
| 17.06.2021 | Capsida Partners With CRISPR Therapeutics To Treat ALS and Friedreich's Ataxia | Thousand Oaks-based startup Capsida Biotherapeutics launched in April with the goal of treating devastating diseases using gene therapy. The company just announced a big break that could accelerate its plans. This week the company inked a d... |
| 17.06.2021 | Two Biotech Companies Team Up to Take On Rare Diseases with No Cure | Thousand Oaks-based startup Capsida Biotherapeutics launched in April with the goal of treating devastating diseases using gene therapy. The company just announced a big break that could accelerate its plans. This week the company inked a d... |
| 03.05.2021 | 140 milioane dolari pentru startup-ul deschis de o cercetătoare româncă alături de alți antreprenori, în SUA | O cercetătoare româncă stabilită în SUA a deschis un startup de biotehnologii în urmă cu 2 ani, alături de alți antreprenori, iar acum au reușit să-și asigure o finanțare totală de 140 de milioane de dolari de la investitori americani din d... |
| 01.05.2021 | Capsida Biotherapeutics Raises $140M in Series A Funding | Capsida Biotherapeutics Inc., a Thousand Oaks, CA-based biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, raised ... |
| 29.04.2021 | Daily funding roundup - April 29th, 2021 | Vectra AI raised $130M; Solidia Technologies landed $78M; Capsida Biotherapeutics secured $50M; Keep Mosaic: Mosaic is a California based financing platform for U.S. residential solar and energy-efficient home improvement projects. Mosaic a... |
| 29.04.2021 | This LA-Based Startup Aims to Permanently Treat Devastating Diseases Like Parkinson’s | A Thousand Oaks startup that is creating gene therapies aimed at permanently treating devastating diseases like Alzheimer's announced Thursday it received $140 million in capital. Capsida Biotherapeutics is joining the gene therapy craze wi... |
| 29.04.2021 | Capsida Uncloaks With $140M In Funding | Thousand Oaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has ... |
| - | Investors have poured $548 million into neuroscience biotechs this year. Meet the 10 startups that have raised the most cash. | Peter Anastasiou, the CEO of Capsida Biotherapeutics. Capsida Biotherapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Neuroscience companies have raised more money from VCs in rec... |